Prostaglandin Receptor

Prostaglandin receptor, a sub-family of cell surface seven-transmembrane receptors, are the G-protein-coupled receptors. There are currently ten known prostaglandin receptors on various cell types. Prostaglandins bind to a subfamily of cell surface seven-transmembrane receptors, G-protein-coupled receptors. These receptors are named: DP1-2-DP1, DP2 receptors, EP1-4-EP1, EP2, EP3, EP4 receptors, FP-FP, IP1-2-IP1, IP2 receptors, TP-TP receptor. The prostaglandins are a group of hormone-like lipid compounds that are derived enzymatically from fatty acids and have important functions in the animal body. There are currently ten known prostaglandin receptors on various cell types.
## Prostaglandin Receptor Inhibitors, Agonists, Antagonists, Activators & Modulators

### (++)-Cloprostenol (D-Cloprostenol)
- **Cat. No.:** HY-107381
- **Purity:** 99.13%
- **Clinical Data:** No Development Reported
- **Size:** 10 mM \times 1 mL, 1 mg, 5 mg, 10 mg, 25 mg

### 16,16-Dimethyl prostaglandin E2 (16,16-dimethyl PGE2)
- **Cat. No.:** HY-106420
- **Purity:** >98.0%
- **Clinical Data:** No Development Reported
- **Size:** 5 mg

### Agnuside (Agnoside)
- **Cat. No.:** HY-N2518
- **Purity:** >98%
- **Clinical Data:** No Development Reported
- **Size:** 5 mg, 10 mg

### AM211 (AM211 free acid)
- **Cat. No.:** HY-13213
- **Purity:** 99.94%
- **Clinical Data:** No Development Reported
- **Size:** 10 mM \times 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

### AZ-1355
- **Cat. No.:** HY-101692
- **Purity:** >98%
- **Clinical Data:** No Development Reported
- **Size:** 1 mg, 5 mg

### (-)-Curine
- **Cat. No.:** HY-N2569
- **Purity:** 99.47%
- **Clinical Data:** No Development Reported
- **Size:** 1 mg, 5 mg

### 2-((E-2-decenoylamino)ethyl 2-(cyclohexylethyl) sulfide
- **Cat. No.:** HY-100287
- **Purity:** >98%
- **Clinical Data:** No Development Reported
- **Size:** 1 mg, 5 mg

### AH 6809
- **Cat. No.:** HY-10418
- **Purity:** 99.47%
- **Clinical Data:** No Development Reported
- **Size:** 10 mM \times 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

### Asaproprant (S-555739)
- **Cat. No.:** HY-16763
- **Purity:** 99.67%
- **Clinical Data:** Phase 2
- **Size:** 10 mM \times 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

### AZ12672857
- **Cat. No.:** HY-136895
- **Purity:** 98.44%
- **Clinical Data:** No Development Reported
- **Size:** 10 mM \times 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

---

**Tel:** 609-228-6898  
**Fax:** 609-228-5909  
**Email:** sales@MedChemExpress.com
AZD1981

Cat. No.: HY-15950

AZD1981 is a potent and selective CRTh2 antagonist; displaces radio-labelled PGD2 from human recombinant DP2 with high potency (pIC50 = 8.4).

Purity: 99.81%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Benorilate (Salipran)

Cat. No.: HY-107795

Benorilate (Salipran) is the esterification product of paracetamol and acetylsalicylic acid. Benorilate has anti-inflammatory, analgesic and antipyretic properties. Benorilate could also inhibit prostaglandin (PG) synthesis.

Purity: 99.80%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

Beraprost sodium

Cat. No.: HY-13569A

Beraprost sodium, a prostacyclin analogue, is a stable and orally active prodrug of PG12. Beraprost sodium is a potent vasodilator, has the potential for pulmonary arterial hypertension treatment through expanding renal vessels, improving microcirculation.

Purity: 99.88%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

BI-671800

Cat. No.: HY-114141

BI-671800 is a highly specific and potent antagonist of chemoattractant receptor-homologous molecule on Th2 cells (DP2/CrTH2), with IC50 values of 4.5 nM and 3.7 nM for PGD2 binding to CrTH2 in hCRTH2 and mCRTH2 transfected cells, respectively.

Purity: 99.96%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Bimatoprost

(AGN 192024)

Cat. No.: HY-80191

Bimatoprost is a prostaglandin analog used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension.

Purity: 99.59%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Bunaprolast

(U66858)

Cat. No.: HY-101987

Bunaprolast (U66858) is a potent inhibitor of LTB4 production in human whole blood. Bunaprolast (U66858) also exhibits significant inhibition of lipoxygenase and TXB2 release.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BW 245C

(AGN 192024)

Cat. No.: HY-101987

BW 245C is a prostanoid DP-receptor (DP1) agonist, used to treat stroke.

Purity: 99.14%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 1 mg

Carbacyclin

(Carbaprostacyclin; Carba-PG12)

Cat. No.: HY-13706

Carbacyclin is a PG12 analogue, acts as a prostacyclin (PG12) receptor agonist and vasodilator, and potently inhibits platelet aggregation.

Purity: >99.0%
Clinical Data: No Development Reported
Size: 1 mg

Carboprost tromethamine

Cat. No.: HY-A0195

Carboprost tromethamine is the synthetic 15-methyl analogue of prostaglandin F2β. Carboprost tromethamine can effectively promote labor contraction of the uterus and significantly reduce the amount of bleeding during and after delivery.

Purity: 98.28%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

CAY10471 Racemate

(TM30089 Racemate)

Cat. No.: HY-13706

CAY10471 Racemate (TM30089 Racemate) is a potent and highly selective prostaglandin D2 receptor CRTH2 antagonist, with a K_i of 0.6 nM for hCRTH2, selective over human thromboxane A2 receptor TP (K_i >10000 nM) or PGD2 receptor DP (K_i, 1200 nM).

Purity: 99.35%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg
<table>
<thead>
<tr>
<th>Compound</th>
<th>Cat. No.</th>
<th>Active Component Description</th>
</tr>
</thead>
</table>
| Cefminox sodium  
(MT-141) | HY-128932 | Cefminox sodium (MT-141) is a semisynthetic cephemycin, which exhibits a broad spectrum of antibacterial activity. |
| Purity: 99.83%  
Clinical Data: Launched  
Size: 25 mg | |
| CI-949 | HY-00364 | CI-949 is an allergic mediator release inhibitor, which inhibits histamine, leukotriene C<sub>4</sub>/D<sub>4</sub> (LTC<sub>4</sub>/LTD<sub>4</sub>) and thromboxane B<sub>2</sub> (TXB<sub>2</sub>) release with IC<sub>50</sub> of 11.4 μM, 0.5 μM and 0.1 μM, respectively. |
| Purity: >98%  
Clinical Data: No Development Reported  
Size: 1 mg, 5 mg | |
| Cloprostenol sodium salt  
(IC 80996 sodium salt) | HY-108415 | Cloprostenol sodium salt (IC 80996 sodium salt) is a potent synthetic prostaglandin analogue, acts as a luteolytic agent, and is a PGF<sub>2α</sub> receptor agonist. |
| Purity: 99.81%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg | |
| Daltroban  
(BM-13505, SKF 96148) | HY-121018 | Daltroban is a selective and specific thromboxane A<sub>2</sub> (TXA<sub>2</sub>) receptor antagonist. Daltroban increase intracellular calcium in vascular smooth muscle cells. Daltroban shows protective effect in reperfusion injury. |
| Purity: 95.62%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg | |
| Darbufelone mesylate  
(CI-1004 mesylate) | HY-101438A | Darbufelone mesylate (CI-1004 mesylate) is a dual inhibitor of cellular PGF<sub>2α</sub> and LT<sub>B</sub><sub>4</sub> production. Darbufelone potently inhibits PGHS-2 (IC<sub>50</sub> = 0.19 μM) but is much less potent with PGHS-1 (IC<sub>50</sub> = 20 μM). |
| Purity: >98%  
Clinical Data: No Development Reported  
Size: 1 mg, 5 mg | |
| Darbufelone  
(CI-1004) | HY-101438 | Darbufelone is a dual inhibitor of cellular PGF<sub>2α</sub> and LT<sub>B</sub><sub>4</sub> production. Darbufelone potently inhibits PGHS-2 (IC<sub>50</sub> = 0.19 μM) but is much less potent with PGHS-1 (IC<sub>50</sub> = 20 μM). |
| Purity: >98.0%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg | |
| Dazoxiben | HY-106067A | Dazoxiben is a potent and orally active thromboxane (TX) synthase inhibitor. |
| Purity: 99.87%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg | |
**Dinoprost**  
(Prostaglandin F2α, PGF2α)  
Cat. No.: HY-12956

Dinoprost (Prostaglandin F2α) is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist. Dinoprost is a luteolytic hormone produced locally in the endometrial luminal epithelium and corpus luteum (CL).

Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

---

**E7046**  
Cat. No.: HY-103088

E7046 is an orally bioavailable and specific EP4 antagonist, with IC50 of 13.5 nM and Kd of 23.14 nM. E7046 exhibits anti-tumor activities.

Purity: 99.60%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

---

**Epibetulinic acid**  
(CJ-023423; RQ-00000007; AAT-007)  
Cat. No.: HY-N0223

Epibetulinic acid, isolated from the root bark of Maytenus cuczoina and the leaves of Maytenus chiapensis, exhibits potent inhibitory effects on NO and prostaglandin E2 (PGE2) production in mouse macrophages (RAW 264.7) stimulated with bacterial endotoxin with IC50 of 0.7 and 0.6...

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

---

**Ethamsylate**  
(Etherylate; Etherlyate)  
Cat. No.: HY-B1074

Ethamsylate is a haemostatic drug, also inhibits biosynthesis and action of those prostaglandins.

Purity: >99.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

---

**Evatanepag**  
(CP-533536 free acid)  
Cat. No.: HY-14839

Evatanepag (CP-533536) is an EP2 selective prostaglandin E2 (PGE2) agonist that induces local bone formation with EC50 of 0.3 nM. IC50 value: 0.3 nM (EC50) Target PGE2 in vitro: CP-533536 is a potent and selective EP2 agonist.

Purity: 99.80%
Clinical Data: Not Developed
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

---

**Ginsenoside Ro**  
(Polysciasaponin P3; Chikusetsusaponin S; Chikusetsusaponin V)  
Cat. No.: HY-N0607

Ginsenoside Ro (Polysciasaponin P3; Chikusetsusaponin S; Chikusetsusaponin V) exhibits a Ca2+ antagonistic antiplatelet effect with an IC50 of 155 μM. Ginsenoside Ro reduces the production of TXA2 more than it reduces the activities of COX-1 and TXA2.

Purity: 99.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

---

**Grapiprant**  
(CJ-023423; RQ-00000007; AAT-007)  
Cat. No.: HY-16781

Grapiprant (CJ-023423) is a selective EP4 receptor antagonist whose physiological ligand is prostaglandin E1 (PGE1). Grapiprant displaces [3H]-PGE1 (1 nM) binding to dog recombinant EP4 receptor with IC50 value of 35 nM and Kd value of 24 nM.

Purity: 99.45%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

---

**Ethersalate**  
(Etyleolate; Ethylelate)  
Cat. No.: HY-101606

Ethersalate inhibits platelet function and decreases thromboxane A2 (TXA2) levels.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

---

**Fevipiprant**  
(QAW039; NVP-QAW039)  
Cat. No.: HY-16768

Fevipiprant (QAW039; NVP-QAW039) is a selective, potent, reversible competitive CRTh2 antagonist with an in vitro dissociation constant KD value of 1.1nM at the CRTh2 receptor and an IC50 value of 0.44 nM for inhibition of PGE2-induced eosinophil shape change in human whole blood.

Purity: 99.63%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg
<table>
<thead>
<tr>
<th>Compound</th>
<th>Cat. No.</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>GSK726701A</td>
<td>HY-112152</td>
<td>GSK726701A is a novel prostaglandin E2 receptor 4 (EP4) partial agonist with a pEC50 of 7.4.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Purity: 98.72%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clinical Data: No Development Reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Size: 10 mM × 1 mL, 5 mg, 10 mg</td>
</tr>
<tr>
<td>Iloprost (Ciloprost; ZK 36374)</td>
<td>HY-A0096</td>
<td>Iloprost (ZK 36374) is a synthetic analogue of prostacyclin PGJ2.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Purity: 99.06%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clinical Data: No Development Reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td>KF 13218</td>
<td>HY-U00231</td>
<td>KF 13218 is a potent, selective and long lasting thromboxane B2 (TXB2) synthase inhibitor with an IC50 value of 5.3±1.3 nM.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Purity: &gt;98%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clinical Data: No Development Reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Size: 1 mg, 5 mg</td>
</tr>
<tr>
<td>KW-8232 free base</td>
<td>HY-100304</td>
<td>KW-8232 free base is an anti-osteoporotic agent, and can reduces the biosynthesis of PGE2.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Purity: &gt;95.0%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clinical Data: No Development Reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Size: 1 mg</td>
</tr>
<tr>
<td>L-161982</td>
<td>HY-108559</td>
<td>L-161982 is a selective EP4 receptor antagonist. L-161982 completely blocks PGE2-induced ERK phosphorylation and cell proliferation of HCA-7 cells. L-161982 alleviates collagen-induced arthritis in mice.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Purity: &gt;98%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clinical Data: No Development Reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Size: 1 mg, 5 mg</td>
</tr>
<tr>
<td>L-798106 (CM9; GW671021)</td>
<td>HY-15274</td>
<td>L-798106 is potent and highly selective prostanoid EP3 receptor antagonist (Ki=0.3 nM), it also has micromolar activities at the EP4, EP1, and EP2 receptors with Ki values of 916 nM, &gt;5000 nM and &gt;5000 nM at EP4, EP1 and EP2, respectively.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Purity: &gt;98.0%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clinical Data: No Development Reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg</td>
</tr>
<tr>
<td>L-888607</td>
<td>HY-111271</td>
<td>L-888607 is a potent, and selective CTHR2 (also known as DP2) agonist with a K_i of 0.8 nM.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Purity: 99.88%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clinical Data: No Development Reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</td>
</tr>
</tbody>
</table>

Tel: 609-228-6898  Fax: 609-228-5909  Email: sales@MedChemExpress.com
Laflunimus (HR325)  
Cat. No.: HY-101813

Laflunimus (HR325) is an immunosuppressive agent and an analogue of the Leflunomide-active metabolite A77 1726. Laflunimus is an orally active inhibitor of dihydroorotate dehydrogenase (DHODH).

Purity: 99.26%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Laropiprant (MK-0524)  
Cat. No.: HY-50175

Laropiprant is a potent, selective DP receptor antagonist with Kᵢ values of 0.57 nM and 2.95 nM for DP receptor and TP Receptor, respectively.

Purity: 99.73%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Latanoprost (PHX441)  
Cat. No.: HY-80577

Latanoprost (PHX441) is a prostaglandin F2α analogue and an agonist for the FP prostanoid receptor, and lowers intraocular-pressure (IOP).

Purity: 99.83%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Misoprostol acid  
Cat. No.: HY-118189

Misoprostol acid is an active metabolite of Misoprostol. Misoprostol is a synthetic analogue of prostaglandin E1 (PGEl), extensively absorbed, and undergoes rapid de-esterification to Misoprostol acid in the gastrointestinal tract after oral administration.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Misoprostol acid D5  
Cat. No.: HY-1181895

Misoprostol acid D5 is deuterium labeled Misoprostol acid. Misoprostol acid is an active metabolite of Misoprostol.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Licarin A ((+-) Licarin A)  
Cat. No.: HY-N2252

Licarin A ((+-) Licarin A), a neolignan isolated from various plants, significantly and dose-dependently reduces TNF-α production (IC₅₀=12.6±0.3 μM) in dinitrophenyl-human serum albumin (DNP-HSA)-stimulated RBL-2H3 cells. Anti-allergic effects.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LCB-2853  
Cat. No.: HY-101700

LCB-2853 is an antagonist of thromboxane A2 (TXA2) receptor, with antiplatelet and antithrombotic activities.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MF498  
Cat. No.: HY-10794

MF498 is a novel and selective E prostanoid receptor 4 (EP4 receptor) antagonist, displayed strong binding affinity for the EP4 receptor with Kᵢ of 0.7 nM.

Purity: 98.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg
### MK-2894

**Cat. No.: HY-10413**

MK-2894 is a potent, selective, orally active and high affinity ($K_i=0.56$ nM) full antagonist against E prostanoid receptor 4 (EP4 receptor) ($IC_{50}=2.5$ nM). MK-2894 possesses potent anti-inflammatory activity in animal models of pain/inflammation and can be used for the research of arthritis.

**Purity:** 98.10%

**Clinical Data:** No Development Reported

**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

### MK-2894 sodium salt

**Cat. No.: HY-10414**

MK-2894 sodium salt is a potent, selective, orally active and high affinity ($K_i=0.56$ nM) full antagonist against E prostanoid receptor 4 (EP4 receptor) ($IC_{50}=2.5$ nM).

**Purity:** 98.09%

**Clinical Data:** No Development Reported

**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

### MK-447

**Cat. No.: HY-100297**

MK-447 is a free radical scavenger, also a nonsteroidal antiinflammatory agent, and enhances the formation of the endoperoxide, PGH₂, and other prostaglandins.

**Purity:** >98%

**Clinical Data:** No Development Reported

**Size:** 1 mg, 5 mg

### MRE-269 (ACT-333679)

**Cat. No.: HY-79593**

MRE-269 is an active metabolite of selepipag, and acts as a selective IP receptor agonist.

**Purity:** 99.46%

**Clinical Data:** No Development Reported

**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

### Nedocromil (FPL 59002)

**Cat. No.: HY-13448**

Nedocromil suppresses the action or formation of multiple mediators, including histamine, leukotriene C₄ (LTC₄), and prostaglandin D₂ (PGD₂).

**Purity:** 98.86%

**Clinical Data:** No Development Reported

**Size:** 10 mM × 1 mL, 5 mg, 10 mg

### NTP42

**Cat. No.: HY-129851**

NTP42 is a thromboxane A2 (TXA2) receptor antagonist with an IC₅₀ of 3.278 nM for antagonizing T prostanoid receptor (TP) mediated [Ca²⁺] mobilization following stimulation of cells with the alternative TP agonist U46609.

**Purity:** 98.43%

**Clinical Data:** No Development Reported

**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

### Omidenepag

**Cat. No.: HY-17642**

Omidenepag is a pharmacologically active form of Omidenepag Isopropyl, is a selective, non-prostanoid EP2 receptor agonist, with an $EC_{50}$ of 1.1 nM. Omidenepag shows binding affinities ($IC_{50}$) 10 nM for h-EP2.

**Purity:** 99.78%

**Clinical Data:** No Development Reported

**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

### Omidenepag isopropyl

**Cat. No.: HY-111406**

Omidenepag isopropyl is a selective EP2 receptor agonist. Omidenepag isopropyl is converted to the active product Omidenepag during corneal penetration, and Omidenepag is a highly selective EP2 receptor agonist.

**Purity:** 98.07%

**Clinical Data:** Launched

**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg
<table>
<thead>
<tr>
<th>Compound</th>
<th>Cat. No.</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ONO-AE3-208 (AE 3-208)</td>
<td>HY-50901</td>
<td>Cat. No.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ONO-AE3-208 is an EP4 antagonist, and suppresses cell invasion, migration, and metastasis of prostate cancer.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Purity: 98.65%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clinical Data: No Development Reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg</td>
</tr>
<tr>
<td>Ozagrel (OKY-046)</td>
<td>HY-B0428</td>
<td>Cat. No.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ozagrel (OKY-046) is a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel is an antiplatelet agent, which selectively inhibits human platelet aggregation with an IC50 of 53.12 μM.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Purity: 99.96%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clinical Data: Launched</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td>Ozagrel hydrochloride (OKY-046 hydrochloride)</td>
<td>HY-804288</td>
<td>Cat. No.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ozagrel hydrochloride (OKY-046 hydrochloride) is a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel hydrochloride is an antiplatelet agent, which selectively inhibits human platelet aggregation with an IC50 of 53.12 μM.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Purity: &gt;98.0%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clinical Data: Launched</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td>Pectolinarin</td>
<td>HY-N0314</td>
<td>Cat. No.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pectolinarin, isolated from Cirsium chanroenicum, possesses anti-inflammatory activity. Pectolinarin inhibits secretion of IL-6 and IL-8, as well as the production of PGE2 and NO.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Purity: 99.89%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clinical Data: No Development Reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Size: 5 mg, 10 mg, 20 mg</td>
</tr>
<tr>
<td>PF-04418948</td>
<td>HY-18966</td>
<td>Cat. No.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PF-04418948 is an orally active, potent and selective prostaglandin EP2 receptor antagonist with an IC50 of 16 nM.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Purity: 99.22%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clinical Data: Phase 1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg</td>
</tr>
<tr>
<td>Prostaglandin D1 (PGD1)</td>
<td>HY-80131</td>
<td>Cat. No.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prostaglandin D1 (PGD1) is a potent vasodilator and activates the prostaglandin D1 (DP) receptor.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Purity: 98.03%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clinical Data: Launched</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Size: 5 mg, 10 mg, 50 mg</td>
</tr>
<tr>
<td>Prostaglandin E2 (Dinoprostone)</td>
<td>HY-101952</td>
<td>Cat. No.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prostaglandin E2 is a hormone-like substance that participate in a wide range of body functions such as the contraction and relaxation of smooth muscle, the dilation and constriction of blood vessels, control of blood pressure, and modulation of inflammation.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Purity: 98.36%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clinical Data: Launched</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
</tbody>
</table>

www.MedChemExpress.com
Quinotolast sodium (FR71021)
Cat. No.: HY-U00027
Quinotolast sodium in the concentration range of 1-100 μg/mL inhibits histamine, LTC4, and PGD2 release in a concentration-dependent manner.
Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ralinepag (APD811)
Cat. No.: HY-16751
Ralinepag is a potent, orally bioavailable and non-prostanoid prostacyclin (IP) receptor agonist, with EC50 of 8.5 nM, 530 nM and 850 nM for human and rat IP receptor and human DP1 receptor, respectively.
Purity: 99.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ramatroban (BAY u3405)
Cat. No.: HY-B0745
Ramatroban is a selective thromboxane A2 (TXA2) receptor (TP) antagonist. Thromboxane A2 Receptor Seratrodast, also known as AA 2414, is a potent and selective thromboxane A2 receptor antagonist. Target: Thromboxane A2 Receptor Seratrodast, also known as AA 2414, is a potent and selective antagonist of the TXA2R (thromboxane A2 receptor).
Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Rebamipide (OPC12759; Proamipide)
Cat. No.: HY-B0360
Rebamipide (OPC12759) is a mucoprotective agent. Rebamipide induces COX-2 expression, increases PGE2 levels, and enhances gastric mucosal defense in a COX-2-dependent manner.
Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Rebamipide D4 (OPC12759 D4; Proamipide D4)
Cat. No.: HY-B03605
Rebamipide D4 (OPC12759 D4) is deuterium labeled Rebamipide. Rebamipide is a mucoprotective agent. Rebamipide induces COX-2 expression, increases PGE2 levels, and enhances gastric mucosal defense in a COX-2-dependent manner.
Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RO1138452 (CAY10441)
Cat. No.: HY-108912
RO1138452 is a potent and selective IP (prostacyclin) receptor antagonist. RO1138452 displays high affinity for IP receptors. In human platelets, pKi is 9.3±0.1; in a recombinant IP receptor system, pKi is 8.7±0.06.
Purity: 98.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RS-601
Cat. No.: HY-U00072
RS-601 is a novel leukotriene D4 (LTD4)/thromboxane A2 (TXA2) dual receptor antagonist, with antiasthmatic activities.
Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Saikogenin D
Cat. No.: HY-N4237
Saikogenin D is isolated from Bupleurum chinense, has anti-inflammatory effects.
Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Selexipag (NS-304, ACT-293987)
Cat. No.: HY-14870
Selexipag (NS-304) is an orally available and potent agonist for the Prostacyclin (PGI2) receptor (IP receptor).
Purity: 99.89%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Seratrodast (AA 2414)
Cat. No.: HY-B0774
Seratrodast (AA 2414) is a potent and selective thromboxane A2 receptor (TP) antagonist. Target: Thromboxane A2 Receptor Seratrodast, also known as AA-2414, is a potent and selective antagonist of the TXA2R (thromboxane A2 receptor).
Purity: 99.68%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg
Setipiprant

(ACT-129968; KYTH-105)

Setipiprant is an orally available, selective CRTH2 antagonist. CRTH2 is a G protein-coupled receptor for PGE2.

Purity: 98.17%
Clinical Data: Phase 3
Size: 10 mM x 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Sulprostone

(SHB 286; CP-34089; ZK-57671)

Sulprostone (SHB 286) is a potent and selective EP3 receptor agonist. Sulprostone (SHB 286) is a prostaglandin E2 (PGE2) analogue and has antilulcer and nonsteroidal abortifacient effects.

Purity: >99.0%
Clinical Data: No Development Reported
Size: 10 mM x 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

Taprenepag

(CP-544326)

Taprenepag (CP-544326) is a potent and selective prostaglandin EP(2) agonist with IC₅₀ of 10 and 15 nM for human and rat EP2, respectively. Taprenepag shows selectivity for EP2 over other EP receptors (IC₅₀s >3200 nM for EP1, EP3, and EP4) and a panel of 37 G protein-coupled receptors.

Purity: 99.26%
Clinical Data: No Development Reported
Size: 10 mM x 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Terbogrel

(BBBV 3085E)

Terbogrel is an orally available thromboxane A2 receptor antagonist and a thromboxane A2 synthase inhibitor, with both IC₅₀ of about 10 nM.

Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Terutroban

(S-18886)

Terutroban is a thromboxane-prostaglandin receptor antagonist.

Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM x 1 mL, 10 mg, 50 mg

TG4-155

(TG4-155)

TG4-155 is a potent, brain-permeant and selective EP2 receptor agonist with a Kᵢ of 9.9 nM. TG4-155 shows low nanomolar antagonist activity against only EP2 and DP1.

Purity: 99.12%
Clinical Data: No Development Reported
Size: 10 mM x 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tiaprost

(Iliren)

Tiaprost is a prostaglandin F₁α (PGF₁α) analogue.

Purity: >98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Timapiprant

(OC000459)

Timapiprant (OC000459) is a potent, selective, and orally active D prostanoid receptor 2 (DP₂, also known as CRTH2) antagonist.

Purity: 98.52%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg

Timapiprant sodium

(OC000459 sodium)

Timapiprant sodium (OC000459 sodium) is a potent, selective, and orally active D prostanoid receptor 2 (DP₂, also known as CRTH2) antagonist.

Purity: 99.91%
Clinical Data: Phase 2
Size: 10 mM x 1 mL, 5 mg, 10 mg, 50 mg
<table>
<thead>
<tr>
<th><strong>Tranilast</strong>&lt;br&gt;(MK-341; SB 252218)</th>
<th><strong>Cat. No.: HY-80195</strong>&lt;br&gt;Tranilast (MK-341) acts as an anti-atopic agent. Tranilast suppresses production of prostaglandin D2 (PGD2, IC&lt;sub&gt;50&lt;/sub&gt; = 0.1 mM). Tranilast exhibits anti-inflammatory and immunomodulatory effects.&lt;br&gt;Purity: 99.46%&lt;br&gt;Clinical Data: Launched&lt;br&gt;Size: 10 mM × 1 mL, 10 mg, 50 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Travoprost</strong>&lt;br&gt;(Fluprostanol isopropyl ester; AL6221; Flu-Ipr)</td>
<td><strong>Cat. No.: HY-80584</strong>&lt;br&gt;Travoprost (Fluprostanol isopropyl ester), an isopropyl ester prodrug, is a high affinity, selective FP prostaglandin full receptor agonist. Travoprost has the ocular hypotensive efficacy and has the potential for glaucoma and ocular hypertension.&lt;br&gt;Purity: 99.99%&lt;br&gt;Clinical Data: Launched&lt;br&gt;Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg</td>
</tr>
<tr>
<td><strong>Treprostinil</strong>&lt;br&gt;(UT-15)</td>
<td><strong>Cat. No.: HY-16504</strong>&lt;br&gt;Treprostinil sodium is a potent DP1 and EP2 agonist with EC&lt;sub&gt;50&lt;/sub&gt; values of 0.6±0.1 and 6.2±1.2 nM, respectively.&lt;br&gt;Purity: &gt;98.0%&lt;br&gt;Clinical Data: Launched&lt;br&gt;Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg</td>
</tr>
<tr>
<td><strong>YM158 free base</strong>&lt;br&gt;(YM-57158)</td>
<td><strong>Cat. No.: HY-U00355</strong>&lt;br&gt;YM158 free base is a potent and selective LTD&lt;sub&gt;4&lt;/sub&gt; and TXA&lt;sub&gt;2&lt;/sub&gt; receptor antagonist with pA&lt;sub&gt;2&lt;/sub&gt; values of about 8.87 and 8.81, respectively.&lt;br&gt;Purity: &gt;98%&lt;br&gt;Clinical Data: No Development Reported&lt;br&gt;Size: 1 mg, 5 mg</td>
</tr>
<tr>
<td><strong>U-46619</strong>&lt;br&gt;(9,11-Methaneoxygen PGH2)</td>
<td><strong>Cat. No.: HY-108566</strong>&lt;br&gt;U-46619 (9,11-Methaneoxygen PGH2) is a stable analogue of thromboxane A2 (TXA2) and acts as a potent TXA2 agonist.&lt;br&gt;Purity: &gt;99.0%&lt;br&gt;Clinical Data: No Development Reported&lt;br&gt;Size: 5 mg (28.5 mM * 500 μL in Methyl acetate)</td>
</tr>
<tr>
<td><strong>Treprostinil sodium</strong>&lt;br&gt;(MK-341 sodium; SB 252218 sodium)</td>
<td><strong>Cat. No.: HY-80195A</strong>&lt;br&gt;Tranilast sodium (MK-341 sodium) acts as an anti-atopic agent. Tranilast suppresses production of prostaglandin D2 (PGD2, IC&lt;sub&gt;50&lt;/sub&gt; = 0.1 mM). Tranilast sodium exhibits anti-inflammatory and immunomodulatory effects.&lt;br&gt;Purity: &gt;98%&lt;br&gt;Clinical Data: Launched&lt;br&gt;Size: 1 mg, 5 mg</td>
</tr>
<tr>
<td><strong>Tranilast sodium</strong>&lt;br&gt;(MK-341 sodium; SB 252218 sodium)</td>
<td><strong>Cat. No.: HY-100441</strong>&lt;br&gt;Treprostinil (LRX-15) is a potent DP1 and EP2 agonist with IC&lt;sub&gt;50&lt;/sub&gt; values of 0.6±0.1 and 6.2±1.2 nM, respectively.&lt;br&gt;Purity: 99.98%&lt;br&gt;Clinical Data: Launched&lt;br&gt;Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg</td>
</tr>
</tbody>
</table>

---

Tel: 609-228-6898  Fax: 609-228-5909  Email: sales@MedChemExpress.com